Drugs & Pharmacology 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 20.
Reviewers for 2012
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Tags: Reviewers for 2012 Source Type: research
On the selectivity of neuronal NOS inhibitors
Conclusion and ImplicationsThe results suggest that l‐VNIO, NPA and 1400W, as well as the newer pyrrolidine‐type inhibitors, cannot be used as neuronal NOS inhibitors in cells without stringent verification. The identification of inhibitors with useable selectivity in cells and tissues remains an important goal.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: B Pigott, K Bartus, J Garthwaite Tags: Research Paper Source Type: research
The inhibitor of volume‐regulated anion channels DCPIB activates TREK potassium channels in cultured astrocytes
Conclusion and ImplicationsOur results indicate that the neuroprotective effect of DCPIB could be due, at least in part, to activation of TREK channels. DCPIB could be used as template to build new pharmacological tools able to increase background K+ conductance in astroglia and neuronal cells.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: L Minieri, H Pivonkova, M Caprini, L Harantova, M Anderova, S Ferroni Tags: Research Paper Source Type: research
Noradrenaline stimulates cell proliferation by suppressing potassium channels via Gi/o‐protein‐coupled α1B‐adrenoceptors in human osteoblasts
Conclusions and ImplicationsNoradrenaline facilitated cell proliferation by regulation of potassium currents in human osteoblasts via Gi/o‐protein‐coupled α1B‐adrenoceptors, not via coupling to Gq‐proteins.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: D Kodama, A Togari Tags: Research Paper Source Type: research
The anti‐cancer agent SU4312 unexpectedly protects against MPP+‐induced neurotoxicity via selective and direct inhibition of neuronal NOS
Conclusions and ImplicationSU4312 exhibited neuroprotection against MPP+ at least partly via selective and direct inhibition of nNOS. Because SU4312 could reach the brain in rats, our study also offered a support for further development of SU4312 to treat neurodegenerative disorders, particularly those associated with NO‐mediated neurotoxicity.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Wei Cui, Zaijun Zhang, Wenming Li, Shengquan Hu, Shinghung Mak, Huan Zhang, Renwen Han, Shuai Yuan, Sai Li, Fei Sa, Daping Xu, Zhixiu Lin, Zhong Zuo, Jianhui Rong, Edmond Dik‐Lung Ma, Tony Chunglit Choi, Simon MY Lee, Yifan Han Tags: Research Paper Source Type: research
Anti‐inflammatory effects of tobramycin and a copper–tobramycin complex with superoxide dismutase‐like activity
Conclusions and ImplicationsAnti‐inflammatory effects of tobramycin in vivo may relate to the spontaneous formation of a copper–tobramycin complex, implying that copper–tobramycin may be more effective therapy.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: M Gziut, HJ MacGregor, TG Nevell, T Mason, D Laight, JK Shute Tags: Research Paper Source Type: research
Effects of μ‐opioid receptor modulation on the hippocampal network activity of sharp wave and ripples
Conclusions and ImplicationsWe found that the SWRs were significantly modulated by three MOR agonists and that the SWRs were very sensitive to subtle changes in the excitation/inhibition balance induced by MOR agonists. Such modulation might underlie the effects of these agonists on hippocampus‐dependent memory.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Panagiotis Giannopoulos, Costas Papatheodoropoulos Tags: Research Paper Source Type: research
4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity
Conclusions and ImplicationMH inhibits growth of human prostate cancer cells through activation of PPARγ, suppression of NF‐κB and arrest of the cell cycle. Thus, MH might be a useful tool for treatment of prostate cancer.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: NJ Lee, JH Oh, JO Ban, JH Shim, HP Lee, JK Jung, BW Ahn, DY Yoon, SB Han, YW Ham, JT Hong Tags: Research Paper Source Type: research
A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABAA receptors
Conclusions and ImplicationsDS2 is the first PAM selective for α4/6βxδ receptors, providing a novel tool to investigate extrasynaptic δ‐GABAA receptors. The effects of DS2 are mediated by an unknown site leading to GABAA receptor isoform selectivity.
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: ML Jensen, KA Wafford, AR Brown, D Belelli, JJ Lambert, NR Mirza Tags: Research Paper Source Type: research
GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery
This article is a commentary on the research paper by Siddiquee et al., pp. 1104–1117 of this issue. To view this paper visit http://dx.doi.org/10.1111/j.1476‐5381.2012.02192.x
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Eugénie Goupil, Stéphane A Laporte, Terence E Hébert Tags: Commentary Source Type: research
ONO‐2506 inhibits spike–wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation
Conclusions and ImplicationsONO‐2506 did not affect traditional convulsive tests but markedly inhibited epileptic phenomena in the genetic epilepsy mouse model. ONO‐2506 enhanced release of inhibitory neuro‐ and gliotransmitters during the resting stage and inhibited tripartite transmission during the hyperactive stage. The results suggest that ONO‐2506 is a novel potential glial‐targeting antiepileptic drug.
Linked ArticleThis article is commented on by Onat, pp. 1086–1087 of this issue. To view this commentary visit http://dx.doi.org/10.1111/bph.12050
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Satoshi Yamamura, Masamitsu Hoshikawa, Kato Dai, Hiromitsu Saito, Noboru Suzuki, Osamu Niwa, Motohiro Okada Tags: Research Paper Source Type: research
PPAR‐γ – a possible drug target for complicated pregnancies
Peroxisome proliferator activated receptors (PPARs) are ligand‐activated transcription factors expressed in trophoblasts, which regulate both cell differentiation and proliferation. In recent years, evidence has linked PPARs to playing an integral role in pregnancy; specifically, PPAR‐β and PPAR‐γ have been shown to play an integral role in placentation, with PPAR‐γ additionally serving to regulate trophoblast differentiation. Recent evidence has shown that PPAR‐γ expression is altered in many complications of pregnancy such as intrauterine growth restriction (IUGR), preterm birth, pre‐clampsia and gestatio...
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Fergus P McCarthy, Aoife C Delany, Louise C Kenny, Sarah K Walsh Tags: Review Source Type: research
IFN‐α subtypes: distinct biological activities in anti‐viral therapy
During most viral infections, the immediate host response is characterized by an induction of type I IFN. These cytokines have various biological activities, including anti‐viral, anti‐proliferative and immunomodulatory effects. After induction, they bind to their IFN‐α/β receptor, which leads to downstream signalling resulting in the expression of numerous different IFN‐stimulated genes. These genes encode anti‐viral proteins that directly inhibit viral replication as well as modulate immune function. Thus, the induction of type I IFN is a very powerful tool for the host to fight virus infections. Many viruses...
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: K Gibbert, JF Schlaak, D Yang, U Dittmer Tags: Review Source Type: research
Do as you would be done by: write as you would wish to read
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Authors: Gordon B Drummond, Sarah L Vowler Tags: Editorial Source Type: research
Issue Information
Source: British Journal of Pharmacology - February 20, 2013 Category: Drugs & Pharmacology Tags: Issue Information Source Type: research
NPY Y1 Receptors Differentially Modulate GABAA and NMDA Receptors via Divergent Signal-Transduction Pathways to Reduce Excitability of Amygdala Neurons
& Anantha Shekhar
Keywords: Epac; glutamate; mood/anxiety/stress disorders; neuropeptide Y; receptor pharmacology; second messengers
Source: Neuropsychopharmacology - February 20, 2013 Category: Neurology Authors: Andrei I MoloshTammy J SajdykWilliam A TruittWeiguo ZhuGerry S OxfordAnantha Shekhar Tags: Epac glutamate mood/anxiety/stress disorders neuropeptide Y receptor pharmacology second messengers Source Type: research
New national IV monograph on Sodium stibogluconate
Source: Medusa
Area: News
A new IV monograph on Sodium stibogluconate is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Updated national IV monograph on Amiodarone hydrochloride
Source: Medusa
Area: News
An updated IV monograph on Amiodarone hydrochloride is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Updated national IV monograph on Desferrioxamine mesilate
Source: Medusa
Area: News
An updated IV monograph on Desferrioxamine mesilate is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Updated national IV monograph on Sodium lactate intravenous infusion, compound
Source: Medusa
Area: News
An updated IV monograph on Sodium lactate intravenous infusion, compound is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Updated national IM monograph on Zuclopenthixol acetate - intermediate acting
Source: Medusa
Area: News
An updated IM monograph on Zuclopenthixol acetate - intermediate acting is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Updated national IV monograph on Filgrastim (Zarzio)
Source: Medusa
Area: News
An updated IV monograph on Filgrastim (Zarzio) is now available from the NHS injectable medicines guide website (Medusa). Please see the link below for access (registration required).
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Department of Health updates HIV outpatient pathway guidance
Source: Department of Health (DH)
Area: News
The Department of Health has published further guidance to support the implementation of the mandatory adult HIV outpatient and Payment by Results currency. This documentation replaces the previously published guidance.
Please see link below for further details.
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Cohort study: Hyperbaric oxygen therapy not effective for diabetic foot ulcers and the prevention of amputation
Source: Diabetes Care
Area: News
A cohort study has found that hyperbaric oxygen (HBO) did not improve wound healing or prevent lower extremity amputation in patients with diabetic foot ulceration
The researchers studied 6,259 individuals representing 767,060 person-days of wound care. In propensity score-adjusted models, individuals receiving HBO were less likely to have healing of their foot ulcer (hazard ratio, 0.68; 95% confidence interval, 0.63-0.73) and more likely to have an amputation (2.37 [1.84-3.04]) than those patients who did not receive HBO.
The authors concluded that the usefulness of HB...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Lancet series on paediatric cancers
Source: Lancet Oncology
Area: News
The Lancet Series on paediatric cancers discusses the following issues:
. New policies to address the global burden of childhood cancers
. New drugs for children and adolescents with cancer: the need for novel development pathways
. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries
. Paediatric cancer in low-income and middle-income countries
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon scanning: Updated survival data for phase II trial of bavituximab for second-line treatment of non-small cell lung cancer
Source: BioSpace
Area: News
Peregrine Pharmaceuticals, Inc. has reported updated survival data from its randomised, double-blind, placebo-controlled phase IIb trial evaluating bavituximab plus docetaxel versus docetaxel plus placebo in 121 patients with second-line stage IIIb or IV non-squamous, non-small cell lung cancer (NSCLC). See previous NELM report for study details.
The data indicate a median overall survival of 11.7 months in the bavituximab arm compared to 7.3 months in the control arm (hazard ratio=0.73; p value=0.217). The results also demonstrated that bavituximab was well-tolerated with no ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
EMA grants orphan drug status to remestemcel-L (ProchymalT) for acute graft versus host disease
Source: BioSpace
Area: News
The European Medicines Agency (EMA) has granted orphan drug designation to remestemcel-L (ProchymalT) for acute graft versus host disease (GvHD).
Prochymal is an intravenous formulation of adult human mesenchymal stem cells that is currently approved in Canada and New Zealand for the management of acute GvHD in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program.
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon scanning: FDA accepts New Drug Application for AnoroT (umeclidinium bromide and vilanterol) for COPD
Source: BioSpace
Area: News
GlaxoSmithKline plc has announced that the New Drug Application for AnoroT, a combination of two investigational bronchodilator molecules: umeclidinium bromide, and vilanterol, for the treatment of chronic obstructive pulmonary disease (COPD), has been accepted by the US Food and Drug Administration (FDA). The once-daily combination medicine is administered using the ElliptaT inhaler.
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon scanning: Phase III (FUSION) results for sofosbuvir in chronic hepatitis C
Source: BioSpace
Area: News
Gilead Sciences has announced topline results from the phase III FUSION study evaluating sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior interferon-based treatment.
In the FUSION study, patients were randomised to either a 12-week (n=103) or 16-week (n=98) course of sofosbuvir 400 mg once daily plus RBV (1,000 or 1,200 mg/day). The primary efficacy endpoint was superiority compared to a predefined historic control sustained virological response (SVR) rate of 25%.
The followin...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
RCT: Bendamustine plus rituximab vs CHOP plus rituximab as first-line treatment for indolent and mantle-cell lymphomas
Source: Lancet
Area: News
Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is considered the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma, however there are no randomised comparative study data to show that this regimen is better than other chemotherapy regimens. Bendamustine plus rituximab is effective for relapsed or refractory disease and based on long-standing experience of its use in Germany, this prospective, randomised, open-label non-inferiority study compared this regimen with ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Meta-analysis: Hydroxyethyl starch associated with mortality and acute kidney injury in critically ill patients
Source: JAMA
Area: News
Hydroxyethyl starches are synthetic fluid products widely used for volume resuscitation but clinical trial data are conflicting and have suggested an increased risk of mortality and acute kidney injury. Furthermore, multiple trials from one researcher have been retracted because of scientific misconduct.
This systematic review and meta-analysis evaluated the association of hydroxyethyl starch on these outcomes with an additional investigation on the influence of the retracted studies.
Investigators searched various databases (to October 2012), reference lists of relevant artic...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
NICE issues costing report and template on its clinical guideline on fertility (CG156)
Source: NICE
Area: News
NICE has published a costing report and template to accompany its clinical guideline on fertility (CG 156).
The report states that the cost of implementing the guideline is outside of the payment by results tariff, therefore providers and commissioners should agree a price locally. NICE anticipates that there will be an increased cost in the commissioning of fertility services.
The report contains estimates on the annual impact of implementing this guideline for a population of 100,000- see links below for further details.
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Vandetanib for metastatic medullary thyroid carcinoma
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
Thyroid cancer is a relatively rare malignancy, representing approximately 1% of all cancers, although it is the most common type of endocrine malignancy. In the UK, there were 2,154 newly diagnosed thyroid cancer cases in 2008 (3.5 cases per 100,000). Medullary thyroid cancer (MTC) is an uncommon histological subtype of thyroid cancer that accounts for approximately 3 to 5% of all thyroid cancer cases (or approximately 0.1 to 0.2 cases per 100,000 population).
Vandetanib (Caprelsa®) is licensed for the treatment of aggressive and...
Source: NeLM - Drug Specific Reviews - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
ALL DAY ALLERGY (Cetirizine Hcl) Capsule [P And L Development Of New York Corporation]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
SEROTONINliquid [BioActive Nutritional, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
ELECTROLYTE 8X (Electrolyte) Powder, For Solution [Vedco, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
HYDROCORTISONEointment [Taro Pharmaceuticals U.S.A., Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
SUPREME (Chloroxylenol) Soap [Brookmeade Hardware Supply Co.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
AMPICILLIN AND SULBACTAMinjection, Powder, For Solution [Hospira, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
FORTAMET (Metformin Hydrochloride) Tablet, Film Coated, Extended Release [Shionogi Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
ORAJEL KIDS MY WAY ANTICAVITY (Sodium Fluoride) Gel, Dentifrice [Church Dwight Co., Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
E MEI SHAN MEDICATED PLASTER (Camphor, Menthol, Methyl Salicylate) Plaster [CHENGDU RONGYAO GROUP SICHUAN CHANGWEI PHARMACEUTICAL CO., LTD.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
RANITIDINE (Ranitidine Hydrochloride) Tablet [Valu Merchandisers Company]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
PETROLEUM SKIN PROTECTANT (White Petrolatum) Jelly [Wal-Mart Stores, Inc]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
LEVOCETIRIZINE DIHYDROCHLORIDEtablet [Camber Pharmaceuticals, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
CEFDITOREN PIVOXILtablet, Film Coated [Pharma RomLev Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
SULFADIAZINEtablet [REMEDYREPACK INC. ]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
BACZOL COLD MEDICINE (Acetaminophen, Phenylephrine Hydrochloride, Dextromethorphan Hydrobromide, And Chlorpheniramine Maleate) Liquid [Lex Inc]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
ACL11RX NERVE BLOCK () Kit [Clint Pharmaceuticals, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
MELATONINliquid [BioActive Nutritional, Inc.]
Updated Date: Feb 20, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
